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Patients with atrial fibrillation in Cantonal Hospital
Zenica: hypertension as the most common modifiable
risk factor
Abstract
Background: Atrial fibrillation (AF) is the most prevalent sustained
cardiac arrhythmia in developed countries. It is a disease of the elderly and it
is common in patients (pts) with structural heart disease. Hypertension,
heart failure and valvular heart disease are predisposing factors to AF. Ob-
jectives: To evaluate predisposing factors for development of AF.
Methods: From June 2000 to January 2011, 2965 consecutive pts with
AF were studied during echocardiographic check-up in Cantonal Hospital
Zenica, Bosnia and Herzegovina. According to the 2-D transthoracic
echocardiography, pts were divided into groups based on dominative under-
lying heart diseases. Electrocardiographically documented AF was subdi-
vided into two groups: transitory and chronic. Binary logistic regression was
used to investigate relationship of gender, age, hypertension, diabetes and
underlying heart diseases with the type of AF.
Results: The median age was 72 years, age range between 16 and 96
years. Chronic AF was observed in 69.9% pts. There were 48.3% of males.
Hypertensive heart disease (HHD) was the most common underlying heart
disease (38.5%) followed by dilated cardiomyopathy (DCM), 25.3%, coro-
nary artery disease (CAD), 14.7% and valvular heart disease (VHD),
11.2%. Lone AF was diagnosed in only 28 pts, mostly in younger males
(median age 49 years, range 29–60, men 71%). Hypertension and diabetes
were found in 72.5% and 17.8% pts, respectively, and primary in females.
Conclusion: The aim of this paper was to elucidate cardiopulmonary
and circulatory comorbidities associated with AF in the largest sample of
patients in Central Bosnia. HHD was by far the most prevalent associated
medical condition in pts with AF. AF without underlying heart disease was
present in only 1%, mostly in younger pts with transitory AF. Chronic AF
was predominant in groups with advanced cardiac remodeling such as
DCM and VHD, in mostly elderly patients.
INTRODUCTION
Atrial fibrillation (AF) is the most common sustained arrhythmia indeveloped countries with prevalence rate reaching 8–10% in pa-
tients aged over 80 years. As a disease of the elderly it is prevalent in pa-
tients with circulatory and structural heart diseases that usually de-
velop due to aging. Presence of lone AF, when concomitant cardiopul-
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younger patients (1-3). Of all comorbidities associated
with development of AF, hypertension is reported as the
most common (4). It has been documented that aggres-
sive treatment of hypertension may result in clinical im-
provement of AF (5). Structural heart disease, such as
valvular heart disease, is also strongly associated with AF.
Regardless of Whether it is rheumatic or degenerative in
origin, disease of the heart valves has long been recog-
nized as a risk factor for AF (6, 7). Besides, development
of AF is considered a marker of disease progression and
an indicator for timing of the valve surgery (8). Lastly, AF
is frequent among patients with coronary artery disease.
Development of AF is rarely a direct correlate of atrium
ischemia. In these patients etiology of AF is considered
secondary because patients with coronary heart disease
often exhibit hypertension and left ventricular dysfunc-
tion which lead to atrial abnormalities (9). AF is there-
fore best considered to be a symptom of a more wide-
spread process that eventually resulted in electrophy-
siological and structural abnormalities of atrium (10).
The aim of this paper was to elucidate circulatory and
cardiac comorbidities in, hitherto, the largest sample of
patients with AF in Central Bosnia, as well as in Western
Balkan, and to match it up to data in published studies.
METHODS
Study population
This study comprised 2965 consecutive patients with
AF who were examined during echocardiographic work-
-up at Cantonal Hospital Zenica, Bosnia and Herzego-
vina, between June 2000 and January 2011. The diagno-
sis of AF was made when characteristic irregular fibrilla-
tory waves in the atrium in conjunction with irregular
QRS complexes were evident on all 12 leads of the sur-
face electrocardiogram (ECG). Patients with electrocar-
diographically confirmed presence of atrial flutter, which
produces more regular sawtooth-type flutter waves, alone
or in combination with atrial fibrillation were excluded.
Electrocardiographically documented AF was classified
into transitory or chronic based on its persistence and du-
ration. Our classification scheme is based on that of the
American College of Cardiology/American Heart Asso-
ciation/European Society of Cardiology (1) with minor
modifications required because of the available data at
the time of work-up. Transitory AF fulfilled the criteria
for paroxysmal or persistent arrhythmia, while chronic
AF comprised cases of long-standing persistent or per-
manent AF.
Patient groups and comorbidity
conditions
ECG was used to detect cardiac conduction diseases
such as left bundle branch block. Hypertension was de-
fined as systolic blood pressure above 140 mmHg, and/or
diastolic blood pressure above 90 mmHg, or implied re-
ceiving blood-pressure-lowering drugs. We defined dia-
betes as the physician is diagnosis of diabetes, or fasting
blood sugar 7 mmol/L. Thyroid dysfunction was de-
fined as hypothyroidism or hyperthyroidism according
to described criteria (11).
According to the 2-D transthoracic echocardiography,
patients were divided into groups based on dominant
underlying heart disease. Systolic dysfunction was con-
sidered when left ventricular ejection fraction (LVEF)
was <50%. If left ventricular (LV) diameter at end-sys-
tole/height was 3.3 cm/m than left ventricular dilata-
tion was present. Pulsed-wave Doppler at the apical po-
sition was used to record mitral inflow between the tips
of the mitral leaflets. Peak velocities of early (E) and
atrial (A) diastolic filling and deceleration time of the
E-wave (DT) were measured and the E/A ratio was cal-
culated. Mild diastolic dysfunction was defined as E/A
< 1 and DT > 240 ms. Severe diastolic dysfunction was
defined as DT < 140 ms and E/A<50 years >2.5, E/A50–70 years
>2, or E/A>70 years >1.5 (12). An abnormal echocardio-
graphy examination identified subjects with LV hyper-
trophy, dilatation, ejection fraction <50%, or mild or se-
vere diastolic dysfunction. Diagnosis of valvular heart
diseases (13) or dilated cardiomyopathy (12) was made
according to the established guidelines or relevant echo-
cardiographic criteria. Hypertensive heart disease was
diagnosed in patients with hypertension and echocardio-
graphic criteria of diastolic dysfunction (12). Patients
with hypertension and concomitant coronary artery dis-
ease or dilated cardiomyopathy or thyroid dysfunction
were classified in appropriate group based on predomi-
nant comorbid disease. Coronary artery disease (CAD)
was defined in patients with myocardial infarction, per-
cutaneous coronary intervention, coronary artery bypass
grafting, or angina according to described criteria (14).
The CAD group excluded patients with echocardiogra-
phic signs of dilated cardiomyopathy. Lone AF was de-
fined as AF presenting in individuals younger than 60
years without clinical or echocardiographic evidence of
cardiopulmonary disease, including hypertension, or ot-
her identifiable cause for the arrhythmia such as hy-
perthyroidism or alcohol abuse (1).
Statistical analysis
Normal continuous variables are presented as mean ±
standard deviations. Categorical variables are presented
as number and percentage of total. Mann-Whitney U test
and Student t test were used to compare the means of
continuous variables. Differences among groups of con-
tinuous variables were determined by analysis of vari-
ance. Comparison of percentages was performed with
the c2 test. Binary logistic regression was used to investi-
gate relationship between gender, age, hypertension, dia-
betes and underlying heart diseases with the type of atrial
fibrillation. Differences were considered significant at P
value of <.05.
RESULTS
The population reported here included 2965 patients
(48.3% male; mean age 71.0±10.9 years). Twenty-eight
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patients met criteria for lone AF (22 male; 48±9.4 years),
whereas the remander of patients presented with comorb
diseases (Table 1). Four major concomitant diseases (hy-
pertensive heart disease, dilated cardiomyopathy, CAD,
valvular heart disease) included almost 90% of investi-
gated sample population. In the remaining sample, ex-
cluding patients with lone AF, thyroid dysfunction was
prevailing, affecting almost 40%, without significant dif-
ference in distribution of hyper- or hypothyroidism. Ot-
her rare causes of AF were pulmonary diseases, such as
chronic obstructive pulmonary disease, followed by alco-
hol abuse, and congenital heart diseases, of which atrial
septal defect was predominant.
Hypertension was the most prevalent condition, af-
fecting 72.5% of patients. This largest group of patients,
that included only cases with hypertension, had freque-
ncy of diastolic dysfunction of 70.7%, regardless of the
type. Patients with dilated cardiomyopathy had CAD in
29.7% of cases (223 patients). Intraventricular block was
dominant cardiac conduction disease with dilated car-
diomyopathy, affecting 49.9% (374 patients); almost half
of cases presented as left bundle branch block (171 pa-
tients, 45.7%). Among patients with valvular heart dis-
ease, 87.8% had primary mitral regurgitation and/or mi-
tral stenosis; the remaining patients manifested aortic
valve disease with structurally remodeled heart (Table 2).
A significant frequency of transitory AF was observed in
younger patients, lone AF (OR=2.28, 95% CI=2.13–8.62)
and in patients with hypertension regardless of the pres-
ence of other concomitant heart diseases (OR=1.7, 95%
CI=1.36–2.14). Chronic AF was noted in 69.9%. Chro-
nic AF was more usual in older (OR=1.04, 95% CI=
1.03–1.05), dilated cardiomyopathy group (OR=2.04,
95% CI=1.31–3.18) and valvular heart disease group
(OR=3.23, 95% CI=1.97–5.32). Binary logistic regres-
sion of analyzed data is shown in Figure 1.
DISCUSSION
To our knowledge, this is the largest observational
study reporting cardiopulmonary as well as other comor-
bidities, including hypertension, associated with AF for
the region of Central Bosnia. Reports evaluating such
distribution are lacking even for Western Balkan.
In our study hypertension was the most prevalent
concomitant disease, affecting more than 70% of patients
with AF. Furthermore, 38.5% of our cases fulfilled the
criteria for hypertensive heart disease. Prior observatio-
nal studies found arterial hypertension in 65–70% of AF
patients (15-17) but only in 25–50% of the general popu-
lation (18). The Euro Heart Survey on Atrial Fibrilla-
tion, which included 5333 patients from 35 European
countries, demonstrated hypertension as the most fre-
quent risk factor (up to 66%) (16). Hypertension was
only more common (84%) in ATRIUM registry, which
enrolled 3667 patients in Germany (19).
It has been reported that, in the presence of hyperten-
sion, the risk of AF increases up to 1.5 fold, making it one
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TABLE 1
Etiological distribution of patients with atrial fibrillation.
HHD DCM CAD VHD Lone AF Other Total
No of pts (%) 1141 (38.5) 749 (25.3) 437 (14.7) 333 (11.2) 28 (0.95) 277 (9.3) 2965
Males (%) 494 (41.2) 436 (58.2) 248 (56.8) 135 (40.5) 22 (79.0) 103 (46.8) 1438 (48.3)
Median age (yrs) 71 72 72 68 48 69 72
Age, range (yrs) 24–96 37–95 44–94 33–90 29–59 16–93 16–96
Transitory AF (%) 414 (34.7) 150 (20.0) 179 (40.9) 54 (16.2) 21 (75.0) 74 (33.5) 892 (30.1)
Hypertension (%) 100.0 65.2 60.4 43.8 0 46.9 72.5
Diabetes (%) 18.8 17.8 27.7 6.6 0 11.8 17.8
Thyroid diseases (%) 0 5,1 4.8 3.9 0 39.7 6.1
Abbreviations: pts, patients; AF, atrial fibrillation; HHD, Hypertensive heart disease; DCM, Dilated cardiomyopathy; CAD, Coro-
nary artery disease, VHD, Valvular heart disease; Lone AF, Lone atrial fibrillation.
TABLE 2
Concomitant diseases in patients with AF.
Concomitant disease Frequency (%) Males (%) Age means and SD, years (range)
Hypertension 2150 (72.5) 43.9 71 ± 9.3 (24–96)
Coronary artery disease 661 (22.3) 60.2 72 ± 9.0 (37–94)
Diabetes 528 (17.8) 34.6 72 ± 8.3 (19–96)
Left bundle branch block 301 (10.2) 49.2 72 ± 8.9 (40–95)
Thyroid dysfunction 180 (6.1%) 19.4 68 ± 8.5 (38–88)
of the most frequent supraventricular arrhythmias in
these patients (20, 21). Because of its high prevalence in
the population, hypertension independently accounts for
more AF cases than any other risk factor (22). Further-
more, when left ventricular hypertrophy developed due
to arterial hypertension, supraventricular tachycardia was
present in 27.3% compared to 12.9% in controls (23).
Pathophysiological mechanisms for development and
sustainment of AF in hypertension include structural
and electrical remodeling induced after distension of left
atrium and pulmonary veins due to pressure overload.
Moreover, action of renin-angiotensin-aldosteron system
generates local atrial inflammation and fibrosis inducing
structural atrial changes which are responsible for persis-
tence of arrhythmia (4). To affirm proposed mechanis-
ms, Medi et al. reported electrophysiological changes of
atria associated with longstanding hypertension in a con-
trolled study on 20 patients with systemic hypertension
and with evidence of ventricular hypertrophy (24). Atrial
remodeling was characterized by global conduction slo-
wing, regional conduction delay, particularly at the crista
terminalis, and increased AF inducibility. Authors con-
cluded that these changes might be in part responsible
for the increased propensity to AF associated with sys-
temic arterial hypertension. Hennersdorf et al. were first
to demonstrate association among the decrease of left
ventricular hypertrophy, the reduction of left atrial diam-
eter and the decrease in the prevalence of paroxysmal AF
in patients receiving antihypertensive therapy (5).
However, despite its leading importance as a highly
prevalent and modifiable risk factor, only some data are
available regarding predictors and outcome of AF in
large populations of subjects with essential hypertension
free of coexisting valvular or coronary heart disease, con-
gestive heart failure, hyperthyroidism, or other predis-
posing conditions (22). In our study, hypertension, re-
gardless of other comorbidities, was by far the most preva-
lent associated medical condition (Table 2). CAD was
present in one out of five patients. Every second paitent
had heart failure, asymptomatic or symptomatic, with di-
astolic and/or systolic dysfunction. Atrial fibrillation in
patients with valvular heart disease presented early in
mitral stenosis and/or regurgitation and while affliction
of aortic valve was fairly uncommon, fibrillation was
more evident in later stages1. While 'rheumatic AF' was a
frequent finding in the past, nowadays there is a clear
shift to non-valvular AF.
In our sample, chronic AF was predominant in mo-
stly elderly groups with advanced cardiac remodeling
such as dilative cardiomyopathy and valvular heart dis-
ease. Aforementioned Euro Heart Survey and ATRIUM
registry had comparable frequency of associated comor-
bidities, with CAD present in up to 36% and 34%, and
heart failure in up to 49% and 43% of cases, respectively.
Frequency of valvular heart disease was reported only for
Euro Heart Survey and was present in up to 40% of pa-
tients. In both studies, permanent AF was associated
with more concomitant conditions, especially structural
heart diseases (16, 19, 25). Finally, our patients had a
high degree of comorbidity and only very few presented
with lone AF (0.95%), which was mostly transitory. This
finding is comparable with other clinical settings, such as
the FALP observational study where only 1.3% (12/903)
of patients were classified as lone AF (26).
We report 17.8% cases of diabetes mellitus among our
patients with AF; we found these cases mostly in women
(64.5%). Similar reports of diabetes have been found in
other population-based case-control studies with odds
ratio in the range of 1.4 to 1.6 (27-30). The reported risk
is higher in long standing treated diabetes and with poor
glycemic control (28). These findings suggest that diabe-
tes represents an independent risk factor for AF and it is
one of the most concomitant diseases in patients with AF.
Diabetes and AF share common antecedents such as hy-
pertension, atherosclerosis and obesity (27, 31). Physio-
logic changes associated with diabetes include increased
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Figure 1. Risk of chronic atrial fibrillation, binary logistic regression model. HHD, hypertensive heart disease; DCM, dilated cardiomyopathy, CHD,
coronary artery disease; VHD, valvular heart disease; Lone, lone atrial fibrillation; BMI, body mass index; HA, hypertension; DM, diabetes
mellitus; TH, diseases of thyroid gland; IVB, intraventricular block.
left atrial size and elevated C-reactive protein and both
findings are associated with heightened risk of AF
(32-34). People with diabetes are at increased risk of
CAD and congestive heart disease, which all may con-
tribute to the development of AF. Concordantly, the num-
ber of diabetes cases in our study was the highest in pa-
tients with concomitant CAD, with the frequency of
27.7%.
Limitations of the study
This study has several limitations. We identified only
AF that came to clinical attention, so some transitory or
asymptomatic cases may have been missed. Moreover,
outpatient 24-hour ECG recording was not part of the
systematical work-up. There was no control sample as
well as randomization. At the time of work-up, data on
duration and pharmacological treatment of diabetes was
not available to us and therefore not included in analysis.
CONCLUSION
Hypertensive heart disease was by far the most preva-
lent associated medical condition in our patient sample.
Aggressive treatment of hypertension may reduce the
risk and postpone the development of AF. Therefore, cli-
nicians should have heightened suspicion for AF in pa-
tients with concomitant cardiovascular diseases, espe-
cially hypertension.
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